Inotuzumab Ozogamicin


Indications and Reactions:

Role Indications Reactions
Primary
Non-hodgkin's Lymphoma 27.3%
Premedication 10.8%
Pain 8.2%
Constipation 5.7%
Hypertension 5.7%
Acute Lymphocytic Leukaemia 5.2%
Prophylaxis 5.2%
Arrhythmia Prophylaxis 3.1%
Infection Prophylaxis 3.1%
Nausea 3.1%
Diffuse Large B-cell Lymphoma 2.6%
Hypercholesterolaemia 2.6%
Hypertriglyceridaemia 2.6%
Neuropathy Peripheral 2.6%
Spondylolisthesis 2.6%
Vomiting 2.6%
Hypotension 2.1%
Prophylaxis Of Nausea And Vomiting 2.1%
Antacid Therapy 1.5%
Antibiotic Therapy 1.5%
Febrile Neutropenia 20.7%
Atrial Fibrillation 17.2%
Septic Shock 10.3%
Alanine Aminotransferase Increased 6.9%
Ascites 3.4%
Capillary Leak Syndrome 3.4%
Fatigue 3.4%
General Physical Health Deterioration 3.4%
Hyponatraemia 3.4%
Left Ventricular Dysfunction 3.4%
Liver Injury 3.4%
Neuropathy Peripheral 3.4%
Neutropenic Sepsis 3.4%
Pleural Effusion 3.4%
Second Primary Malignancy 3.4%
Urinary Tract Infection 3.4%
Venoocclusive Liver Disease 3.4%
Secondary
Non-hodgkin's Lymphoma 38.8%
Diffuse Large B-cell Lymphoma 14.0%
Prophylaxis 7.5%
B-cell Lymphoma 6.5%
Product Used For Unknown Indication 6.5%
Constipation 4.2%
Lymphoma 4.2%
Hypertension 3.2%
Abdominal Pain 2.1%
Mantle Cell Lymphoma 2.1%
Infection Prophylaxis 1.7%
Premedication 1.7%
Diabetes Mellitus 1.1%
Herpes Zoster 1.1%
Anxiety 1.0%
Pyrexia 1.0%
Conjunctivitis 0.8%
Depression 0.8%
Gastritis 0.8%
Hypokalaemia 0.8%
Thrombocytopenia 16.0%
Hyperbilirubinaemia 12.3%
Nodular Regenerative Hyperplasia 7.4%
Engraft Failure 4.9%
Ileitis 4.9%
Pneumonia 4.9%
Respiratory Failure 4.9%
Thrombophlebitis 4.9%
Tumour Lysis Syndrome 4.9%
Venoocclusive Liver Disease 4.9%
Chills 3.7%
Febrile Neutropenia 3.7%
Neutropenic Sepsis 3.7%
Thrombosis 3.7%
Ascites 2.5%
Dehydration 2.5%
Hepatic Fibrosis 2.5%
Hepatitis 2.5%
Lung Infiltration 2.5%
Mallory-weiss Syndrome 2.5%

Drug Data